IL202660A0 - Lyophilized immunoglobulin formulations and methods of preparation - Google Patents

Lyophilized immunoglobulin formulations and methods of preparation

Info

Publication number
IL202660A0
IL202660A0 IL202660A IL20266009A IL202660A0 IL 202660 A0 IL202660 A0 IL 202660A0 IL 202660 A IL202660 A IL 202660A IL 20266009 A IL20266009 A IL 20266009A IL 202660 A0 IL202660 A0 IL 202660A0
Authority
IL
Israel
Prior art keywords
preparation
methods
immunoglobulin formulations
lyophilized
lyophilized immunoglobulin
Prior art date
Application number
IL202660A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of IL202660A0 publication Critical patent/IL202660A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL202660A 2007-06-14 2009-12-10 Lyophilized immunoglobulin formulations and methods of preparation IL202660A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92913307P 2007-06-14 2007-06-14
US12/138,075 US20090208492A1 (en) 2007-06-14 2008-06-12 Lyophilized Immunoglobulin Formulations and Methods of Preparation
PCT/US2008/066990 WO2008157409A1 (fr) 2007-06-14 2008-06-13 Formulations d'immunoglobuline lyophilisées et procédés de préparation

Publications (1)

Publication Number Publication Date
IL202660A0 true IL202660A0 (en) 2011-08-01

Family

ID=40156638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202660A IL202660A0 (en) 2007-06-14 2009-12-10 Lyophilized immunoglobulin formulations and methods of preparation

Country Status (15)

Country Link
US (1) US20090208492A1 (fr)
EP (1) EP2167126A4 (fr)
JP (1) JP2010530003A (fr)
KR (1) KR20100038100A (fr)
CN (1) CN101827608A (fr)
AU (1) AU2008265930A1 (fr)
BR (1) BRPI0812561A2 (fr)
CA (1) CA2691855A1 (fr)
CO (1) CO6251275A2 (fr)
EA (1) EA201000018A1 (fr)
EC (1) ECSP099837A (fr)
IL (1) IL202660A0 (fr)
MA (1) MA31519B1 (fr)
MX (1) MX2009013558A (fr)
WO (1) WO2008157409A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397034A1 (fr) 2005-07-14 2011-12-21 Lithera, Inc. Formulation lipolytique améliorée à libération prolongée pour le traitement régional des tissus adipeux
PL2993186T3 (pl) 2008-03-14 2020-02-28 Biocon Limited Przeciwciało monoklonalne i sposób jego otrzymywania
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
PL3721904T3 (pl) * 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
US20110224176A1 (en) * 2010-01-15 2011-09-15 Lithera, Inc. Lyophilized Cake Formulations
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
WO2011147921A1 (fr) 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
PT2616090T (pt) * 2010-09-17 2023-10-16 Takeda Pharmaceuticals Co Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro
EA201270784A1 (ru) 2010-11-24 2013-04-30 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания
LT2691112T (lt) * 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
CA2868401C (fr) * 2012-03-26 2021-08-24 Sanofi Preparations d'anticorps igg4 stables anti-cxcr5
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN105189559B (zh) 2013-03-15 2021-07-13 塔科达有限责任公司 抗体制剂及其用途
EP3024485B1 (fr) 2013-07-23 2020-11-18 Biocon Limited Utilisation d'un partenaire de liaison de cd6 et procédé associé
WO2017015198A1 (fr) * 2015-07-17 2017-01-26 Coherus Biosciences, Inc. Formulations aqueuses stables de natalizumab
JP7020913B2 (ja) 2015-09-07 2022-02-16 持田製薬株式会社 アルギン酸凍結乾燥製剤
WO2018068012A1 (fr) 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Protéine lyophilisée stable à la température ambiante
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
EP3618871A4 (fr) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019198100A1 (fr) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Formulation d'anticorps
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
US20210401982A1 (en) * 2018-04-10 2021-12-30 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
JP2022532965A (ja) * 2018-11-21 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度タンパク質製剤
WO2020172002A1 (fr) 2019-02-18 2020-08-27 Eli Lilly And Company Formulation d'anticorps thérapeutique
CN112538111B (zh) * 2020-12-09 2022-04-29 深圳市亚辉龙生物科技股份有限公司 新冠病毒单链抗体及质控品和制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
ES2338218T3 (es) * 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
PT3417875T (pt) * 2003-02-10 2020-08-24 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins

Also Published As

Publication number Publication date
JP2010530003A (ja) 2010-09-02
EA201000018A1 (ru) 2010-06-30
ECSP099837A (es) 2010-01-29
EP2167126A1 (fr) 2010-03-31
BRPI0812561A2 (pt) 2014-10-29
AU2008265930A1 (en) 2008-12-24
MA31519B1 (fr) 2010-07-01
US20090208492A1 (en) 2009-08-20
CN101827608A (zh) 2010-09-08
KR20100038100A (ko) 2010-04-12
EP2167126A4 (fr) 2012-03-07
WO2008157409A1 (fr) 2008-12-24
MX2009013558A (es) 2010-03-08
CO6251275A2 (es) 2011-02-21
WO2008157409A8 (fr) 2010-03-11
CA2691855A1 (fr) 2008-12-24

Similar Documents

Publication Publication Date Title
IL202660A0 (en) Lyophilized immunoglobulin formulations and methods of preparation
IL262205A (en) Protein formulations and methods for their preparation
IL195794A0 (en) Lyophilized formulations of anti-egfr antibodies
IL255813A (en) Compositions of 5-fluorocytosine and their uses
EP2152304A4 (fr) Compositions thérapeutiques à base de nanoémulsion et leurs procédés d'utilisation
IL208457A0 (en) Compositions and methods for the preparation of nanoemulsions
EP2212432A4 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
EP2021455A4 (fr) Système de préparation de cytoblocs et procédés d'utilisation associés
EP2099321A4 (fr) Compositions de lait humain et procédés destinés à fabriquer et utiliser ces compositions
IL206978A0 (en) Powdered protein compositions and methods of making same
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
ZA201203709B (en) Immunogenic compositions and methods
PL2066339T3 (pl) Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
PT2099321T (pt) Composições de leite humano e métodos de fabrico e utilização das mesmas
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
ZA200906516B (en) Novel human anti-R7V antibodies and uses thereof
EP2376089A4 (fr) Compositions de vaccins contre le cancer et leurs méthodes d' utilisation
ZA201101214B (en) Formulations of canfosfamide and their preparation
EP2381929A4 (fr) Composition pharmaceutique d'une formule lyophilisée et sa méthode d'élaboration
ZA200909090B (en) Lyophilized immunoglobulin formulations and methods of preparation
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
IL192552A0 (en) Dnt-succinate and methods of preparation thereof
IL192553A0 (en) Dnt-fumarate and methods of preparation thereof
IL190726A0 (en) Dnt-benzenesulfonate and methods of preparation thereof
AU2007906531A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions